Who Paid My Doc
Alicia King
Neuromusculoskeletal Medicine & OMM Sikeston, MO Doctor of Osteopathy
NPI 1255884359 CMS profile 1737172
102 Hospitality Dr, Sikeston, MO 63801
General payments
$6,667
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Alicia King of Sikeston, MO is reported in the CMS Open Payments database as having received $6,667 across 311 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 93rd percentile of Neuromusculoskeletal Medicine & OMM profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,388 | 69 | |
| 2024 | General | $1,774 | 70 | |
| 2023 | General | $1,418 | 63 | |
| 2022 | General | $1,106 | 63 | |
| 2021 | General | $909 | 43 | |
| 2019 | General | $72 | 3 |
Beside peers
- Alicia King
- Neuromusculoskeletal Medicine & OMM median
- Middle half of Neuromusculoskeletal Medicine & OMM
- National median
In program year 2025, general payments to Alicia King were reported at $1,388. Among 217 Neuromusculoskeletal Medicine & OMM profiles paid that year, the median was $119 and the middle half received between $36 and $380.
Show as a table
| Year | Alicia King | Neuromusculoskeletal Medicine & OMM median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $72 | $92 | $27–$283 | $163 |
| 2020 | $0 | $85 | $20–$411 | $114 |
| 2021 | $909 | $120 | $32–$548 | $132 |
| 2022 | $1,106 | $96 | $32–$518 | $149 |
| 2023 | $1,418 | $92 | $33–$328 | $160 |
| 2024 | $1,774 | $122 | $35–$378 | $164 |
| 2025 | $1,388 | $119 | $36–$380 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 125 drugsPart D claims
5,769
Drug cost
$476,353
Branded share of claims
28.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 67 | $73,624 | |
| Vraylar Cariprazine Hcl | Brand | 18 | $37,884 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 43 | $31,697 | |
| Farxiga Dapagliflozin Propanediol | Brand | 24 | $27,378 | |
| Xarelto Rivaroxaban | Brand | 30 | $25,445 | |
| Jardiance Empagliflozin | Brand | 26 | $21,926 | |
| Caplyta Lumateperone Tosylate | Brand | 11 | $20,080 | |
| Rexulti Brexpiprazole | Brand | 12 | $19,286 | |
| Creon Lipase/Protease/Amylase | Brand | 11 | $16,260 | |
| Buprenorphine | Generic | 48 | $15,655 |
The 10 drugs with the highest cost, of 125 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 526 Part D prescribers listed as Osteopathic Manipulative Medicine; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 29 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| Leqembi |
|
$405 | — | — |
| VOQUEZNA |
|
$175 | — | — |
| VRAYLAR |
|
$160 | 18 | — |
| Austedo XR |
|
$122 | — | — |
| REXULTI |
|
$122 | 12 | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See more in the dashboard: 25 with a free account, all 29 with PatronRecords
311 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Neuromusculoskeletal Medicine & OMM in Missouri
Brent Dixon
Neuromusculoskeletal Medicine & OMM · Kirksville, MO
Rajiv Yadava
Neuromusculoskeletal Medicine & OMM · St Louis, MO
Chelsey Stull
Neuromusculoskeletal Medicine & OMM · Kirksville, MO
Heather Bird
Neuromusculoskeletal Medicine & OMM · Kirksville, MO
Alexander Frantzis
Neuromusculoskeletal Medicine & OMM · Kirksville, MO
Ying Wang
Neuromusculoskeletal Medicine & OMM · Kirksville, MO
Related records
Neuromusculoskeletal Medicine & OMM in Missouri
Practitioners in the same specialty and state, ranked by reported value.
All Neuromusculoskeletal Medicine & OMM
Everyone recorded under this specialty, nationwide.
Doctors in Missouri
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.